NCT01666353View on ClinicalTrials.gov

PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 16, 2012

Primary Completion Date

June 2, 2014

Study Completion Date

December 4, 2018

Conditions
MelanomaRenal Cell Carcinoma (RCC)Non-small Cell Lung Cancer (NSCLC)
Interventions
RADIATION

PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG)

PET/CT imaging with \[18F\] 2-deoxy-2-(18F)fluoro-D-glucose (FDG) is a potent diagnostic tool and is able to detect melanomas and other tumors, some of which are undetectable by CT.

Trial Locations (1)

21287

Johns Hopkins University, Baltimore

Sponsors
All Listed Sponsors
collaborator

Melanoma Research Alliance

OTHER

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER